ESMO - European Society for Medical Oncology’s Post

#MAP2024: In just ten years, next-generation sequencing (NGS) has shifted from experimental use to routine practice in #CancerDiagnostics. However, the challenge remains: how do we effectively harness this wealth of genomic data for clinical benefit? Read the full article by Elli Papaemmanuil  in #ESMODailyReporter 📌https://ow.ly/XmFz50TNv7K

Studies presented at #MAP2024 have shown that sequencing techniques have a wider range of applications in #CancerTreatment. Whole-genome sequencing and single-cell sequencing can offer valuable insights, not only for identifying new therapy targets but also for assessing minimal residual disease and overcoming treatment resistance. Find out more in the #ESMODailyReporter article 📌https://ow.ly/ISLu50TNsi6

👉Understanding #LeptomeningealMetastasis is essential for healthcare professionals involved in the care of cancer patients. Listen to the experts and get best practice recommendations applicable to real world cases for the treatment of this serious condition. 🔗Register with your ESMO account: https://ow.ly/Frkr50TNiX1 lizza hendriks Henk van Halteren Wolfgang Prof Wick

Three studies presented at #MAP2024 showcase the potential of circulating tumour cells (CTCs), exosomal microRNA (exo-miRNA), and cell-free RNA (cfRNA) in #CancerDetection and #ProgressionPrediction. ➡ CTCs in #ColorectalCancer: Significant reductions in CTCs were observed after 3 months of CAPOX treatment in patients with stage III #ColorectalCancer, suggesting CTCs as a valuable prognostic biomarker. ➡ Exo-miRNA in #BreastCancer: developing an exo-miRNA panel shows promise for metastasis prediction, marking an important step in early cancer detection. ➡ cfRNA for Multicancer Detection: Innovative cfRNA-based tests are being developed to identify cancer-specific biomarkers, aiming for early and accurate detection. Full commentary by Nicola Fusco on the #ESMODailyReporter 📌https://ow.ly/faZw50TMIcq

New insights into endocrine therapy resistance in #BreastCancer were unveiled at #MAP2024, providing important information for guiding treatment. To learn more, read the #ESMODailyReporter article commented by Lajos Pusztai 👉https://ow.ly/jiUc50TMtO1

#MAP2024: Advances in spatial transcriptomics technology have revolutionised our understanding of tumour biology. This technology allows researchers to pinpoint gene activity within different parts of a tumour and its microenvironment, revealing previously unexplored heterogeneity and genetic alterations. These insights have significant clinical implications, including the potential for early diagnostics, predicting metastasis, and identifying new therapeutic targets. 📌Read the Opinion by Joakim Lundeberg in the #ESMODailyReporter https://ow.ly/l3KF50TMszR

A month ago, the ESMO Women for Oncology (W4O) Forum took place during #ESMO24 with a focus on "Empowering women in oncology: exploring solutions to today’s challenges across oncology fields." Panellists from various medical fields gathered for a thought-provoking discussion on empowering women in oncology. The conversation highlighted key challenges and offered practical solutions to achieve #GenderEquity in professional practice. It starts by recognising the issues and acknowledging their impact. Collaboration, building supportive structures, and taking decisive steps — with the right people, resources, and commitment — are crucial to making change happen. Looking back on the photos from the Forum at #ESMO24, we also look ahead to continuing the conversation at ESMO Asia 2024. 📅Save the date: Join us at the #ESMOW4O Forum at #ESMOASIA24 on Friday, 6 December, 13:45-14:30 SGT in the Discussion Hub. Helena Linardou Jean-Yves Blay

📣 During the patient session on 11 October 2024 at HDIO Congress, a Croatian-language version of the ESMO Patient Guide on Bone Health in Cancer was presented. 👉 This guide was translated by Sve za Nju in collaboration with HDIO. 🔗 https://ow.ly/vIEG50TKuF7 Photo (from left to right): Dragan Trivanović, Ljiljana Vukota, Stjepko Pleština i Margareta Benković. SVE za NJU udruga

Adjuvant therapy using anti-programmed cell death protein 1 (PD-1) blockade with pembrolizumab or nivolumab is the current standard of care for stage IIB or higher #melanoma. Both agents, approved by the FDA and EMA, have shown significant efficacy in the KEYNOTE-716 and CheckMate 76K studies. At #ESMO24, updated data from the two studies reaffirmed the role of PD-1-based immunotherapy in the adjuvant setting. ➡️The KEYNOTE-716 study demonstrated that adjuvant pembrolizumab significantly prolongs recurrence-free survival (RFS) and distant-metastasis free survival (DMFS) in patients with resected stage IIB or IIC melanoma. ➡️The CheckMate 76K trial highlighted nivolumab’s efficacy in reducing the risk of recurrence or death and distant metastasis in resected stage IIB/C melanoma. 👇Full article available in the #ESMODailyReporter https://ow.ly/1YFz50TJpUC #Melanoma #Immunotherapy #CancerResearch

In oncology, cancer prevention has a critical role. Today, on #WorldMentalHealthDay, let us focus also on preventing #burnout of #OncologyProfessionals and support their #wellbeing so they can also actively contribute to #cancerprevention. ESMO recognises that also #oncologists need to be cared for so that they can provide the best possible care for their patients. The #ESMO4Carers initiative aims to help destigmatise #burnout and its connected (mental) health issues and ultimately increase awareness of the importance of oncologists’ wellbeing. Discover #MedicalOncologists’ personal reflections about this crucial topic. Stay tuned for more #ESMO4Carers content amplifying the voices of the #ONEoncologycommunity.  Take the opportunity to join the conversation about #ProfessionalWellbeing. #MentalHealth #PreventBurnout #MentalHealthMatters #BurnoutAwareness #Resilience Susana Banerjee, Jonathan Lim, Elena Elez Fernández, MD PhD, John Haanen, Claire Hardy PhD CPsychol, Krithika Murali, Christoph Oing, MD PhD, Kevin Punie